Physician profile
Supna B Lowery
NPI 1558308502
$958.14
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $190 · 2021: $185.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $135.00 | 2021 | |
| Novo Nordisk INC | $130.09 | 2019-2020 | |
| Lilly USA, LLC | $105.38 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $77.75 | 2019-2020 | |
| Abbott Laboratories | $49.99 | 2021 | |
| Amarin Pharma, INC. | $49.31 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.15 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $46.60 | 2019-2020 | |
| Ibsa Pharma INC. | $46.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $39.07 | 2019-2020 | |
| Abbvie INC. | $39.04 | 2019 | |
| Merck Sharp & Dohme LLC | $37.70 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $30.72 | 2019-2020 | |
| Corcept Therapeutics | $24.69 | 2019 | |
| Dexcom, INC. | $22.38 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $17.76 | 2019 | |
| Companion Medical, INC. | $16.64 | 2019 | |
| Valeritas, INC. | $15.63 | 2019 | |
| Insulet Corporation | $14.99 | 2019 | |
| Amneal Pharmaceuticals LLC | $11.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Supna Lowery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.